Introduction {#sec1}
============

The sustained attention to response task (SART) has been developed to detect clinically relevant lapses in attention. It represents a simple and quantitative task of executive functions that has been used to capture attentional impairments in different neurodegenerative diseases ([@ref36]; [@ref45]; [@ref46]; [@ref47]). Drifts in attention are captured by a failure to inhibit motor responses to targets (i.e., commission errors). As the task requires only button press responses, it is suitable for performing during EEG recording with little to no electromyographic artifacts. Recently, SART-generated event-related potentials (ERPs) time-locked to Go and NoGo trials have been interrogated in healthy individuals using quantitative electroencephalography (EEG). These ERPs have individual peaks which relate to sensory detection ("P1" and "N1") ([@ref48]), motor control ("N2"), and attentional engagement ("P3"). The latter two peaks are typically larger during correct response withholding ([@ref44]). By combining SART with EEG, distinct indices of the neural network activities required for different aspects of task performance can therefore be determined. This facilitates specific interrogation of the sequentially engaged sensory, motor, and cognitive networks on a millisecond-by-millisecond basis in a quantitative, economical manner. Further, by requiring both motor and cognitive performance, the SART is expected to engage networks that bridge cognitive and motor functions, as opposed to tasks that demand only the individual functions. This makes SART a very suitable candidate for interrogating the cortical pathology in neurological conditions which cause both motor and executive decline, including amyotrophic lateral sclerosis (ALS), Huntington's disease, and Parkinson's disease([@ref14]).

Despite these advantages, the cortical regions engaged by the SART remain unclear. Low-resolution sensor-level topographies have indicated frontoparietal engagement during the task ([@ref44]; [@ref37]), and dorsolateral prefrontal and anterior cingulate malfunctioning during SART has been reported in Huntington's disease ([@ref3]). However, the sources of the SART ERPs in healthy individuals have yet to be reported in high spatial and temporal resolution.

Such source-resolved measures could provide important insights into and biomarkers of different cognitive and/or motor neurodegenerations, such as occurs in the neurodegenerative condition ALS, for which differential diagnostic markers are urgently required.

ALS is the most common form of motor neuron disease and is characterized by the presence of upper and lower motor neuron degeneration. Clinical ([@ref11]; [@ref32]), neuroimaging ([@ref38]), and neuropathological ([@ref15]) evidence have demonstrated extensive additional nonmotor involvement; however quantitative measurement of this decline in cognition and behavior in ALS remains challenging.

Detailed neuropsychological assessment with appropriate adjustments for motor impairment has provided information on the nature and frequency of different cognitive domain impairments in ALS ([@ref32]). However, these types of assessments are excessively time-consuming for clinical trials, in some instances are subject to learning effects, and are insensitive to early, presymptomatic network deterioration. Screening tools, such as the Edinburgh cognitive and behavioral screen (ECAS) for ALS, are useful in a clinical setting but have limited utility in clinical trials and are not sufficiently sensitive for a detailed assessment of cognitive/behavioral change ([@ref33]). Function magnetic resonance imaging (fMRI) and positron emission tomography (PET) have been used to measure cortical activity during specific tasks, but these technologies are limited by cost ([@ref25]), low temporal resolution, and variance across different scanners ([@ref28]).

By contrast, we and others have recently demonstrated how the source localization of EEG facilitates spatially and temporally precise functional imaging of ALS cortical pathology ([@ref9]; [@ref26], [@ref27]). Therefore, given the motor and cognitive pathology of ALS, measurement of SART-associated ERPs using source-resolved EEG provides an opportunity to simultaneously interrogate motor and cognitive network functions and investigate their relationship to symptomatic impairments.

Here, we have spatially resolved the sources of these cognitive indices in healthy individuals and patients with ALS by linearly constrained minimum variance (LCMV)-based source imaging. We demonstrate how quantifying changes in SART--ERP indices and their relation to cognitive and motor symptoms facilitate the investigation of cortical malfunction relating to cognitive impairment in ALS.

Materials and Methods {#sec2}
=====================

Ethical Approval {#sec3}
----------------

Ethical approval was obtained from the ethics committee of St James's Hospital (REC reference: 2017-02). All participants provided written informed consent before participation. All work was performed in accordance with the Declaration of Helsinki.

Participants {#sec4}
============

Recruitment {#sec5}
-----------

Patients were recruited at the Irish National ALS specialty clinic in Beaumont Hospital. Healthy controls included appropriately consented, neurologically normal, age-matched individuals recruited from an existing population-based control bank.

Inclusion Criteria {#sec6}
------------------

Patients were over 18 years of age and diagnosed within the previous 18 months with possible, probable, or definite ALS in accordance with the El Escorial revised diagnostic criteria ([@ref24]).

Exclusion Criteria {#sec7}
------------------

Exclusion criteria included any diagnosed psychological, neurological, or muscular disease other than ALS, use of CNS medications (e.g., antidepressants, antiseizure medication) except riluzole, inability to participate due to ALS-related motor decline (e.g., inability to sit in the chair for the required time or click the mouse to respond), or evidence of significant respiratory insufficiency. Participants were also rescheduled if they slept two or more hours below normal the night before the session and were asked to abstain from consuming alcohol the night before the recording.

Demographics and Characteristics of Patients and Controls {#sec8}
---------------------------------------------------------

Patient and control characteristics are summarized in [Table 1](#TB1){ref-type="table"}. None of the participants met the criteria for FTD diagnosis. One patient was using noninvasive ventilation at nighttime but was clinically asymptomatic with respect to respiratory impairment and had ALS functional rating scale revised (ALSFRS-R) orthopnea and dyspnea scores of 3 (out of 4).

###### 

Characteristics of ALS patients and controls

                                                     Patients           Controls
  -------------------------------------------------- ------------------ ------------------
  *n*                                                23                 33
  Mean age at EEG \[range\] (years)                  63 \[32--78\]      63.21 \[46--82\]
  Gender (f/m)                                       3/20               17/16
  Site of onset (spinal/bulbar/thoracic)             17/5/1             N/A
  Mean disease duration \[range\] (months)           20.01 \[4--42\]    N/A
  Handedness (right/left/ambidextrous)               22/0/1             31/2/0
  C9orf72+                                           3                  Untested
  Mean ALSFRS-R score \[range\]                      38.24 \[24--43\]   N/A
  Mean ECAS total score \[*n* abnormal\]             105.33 \[3\]       Untested
  Mean ECAS ALS-specific score \[*n* abnormal\]      78.47 \[3\]        Untested
  Mean ECAS ALS-nonspecific score \[*n* abnormal\]   26.65 \[2\]        Untested

Handedness was determined by the Edinburgh handedness index. ECAS scores are out of a maximum total score of 136, ALS-nonspecific score of 36, and ALS-specific score of 100. C9orf72+ − carrying a repeat expansion of the C9orf72 gene. ECAS: Edinburgh cognitive and behavioral assessment scale. *N* abnormal: number of participants scoring below the abnormality cutoff score, accounting for years of education.

Experimental Paradigm {#sec9}
=====================

Task Design {#sec10}
-----------

EEG was recorded across 128-channels during 4 × 5-min-long consecutive sessions during which participants undertook the SART. Participants were seated 1 ± 0.1 m from a computer monitor where numbers one to nine in single-digit format were appearing in a random order for 250 ms, using Presentation software (Neurobehavioral Systems Inc.). Digits were presented in light gray (RGB code: 250, 250, 250 from 255) on a black background to reduce discomfort associated with the bright light from purely white numbers, reported during protocol testing. Font size was randomized between 100, 120, 140, 160, and 180 points to avoid participants using a perceptual template of the number 3s features for target recognition and to encourage cognitive processing of the numerical value ([@ref36]). Each stimulus was followed by an interstimulus interval of randomized duration between 1120 and 1220 ms during which time a black screen was presented. Responses were registered by clicking the left button of a computer mouse with the right index finger. Each recording session contained 252 trials of which the number 3 appeared at random in 11% of trials. During these sessions lights were turned off, and experimenters were outside the room to avoid visual/auditory distractions. Online performance and EEG measures were monitored by the experimenter in the neighboring recording room. Appropriate break times were provided to minimize fatigue. Five behavioral measures of performance were captured: NoGo accuracy (percentage of three-digit stimuli followed by response omission), Go accuracy (percentage of nonthree digit stimuli followed by a response in the permitted time window), total accuracy (combined NoGo and Go accuracy), anticipation (clicking less than 150 ms after a go stimulus), and response time.

Participant Instructions {#sec11}
------------------------

At the beginning of the session, the task was explained to participants using the following instructions: Participants were instructed to click the left mouse button every time they saw a number except for the number 3. Participants were requested to equally prioritize speed and accuracy as both were used as measures of performance. They were asked to refrain from lifting their finger away from the mouse button between clicks as this would increase response time measures. Instructions to use their finger only to click the mouse, avoiding tension in the arm and shoulder, and to reduce noise in the EEG signal were also given. Participants were then given one practice round to ensure they understood the task, which had up to 45 trials (without performance being measured), and it was performed under supervision of the experimenter.

Data Acquisition {#sec12}
================

EEG Data {#sec14}
--------

EEG recordings were conducted in the Clinical Research Facility at St. James's Hospital, Dublin using a BioSemi ActiveTwo system (BioSemi B.V.) within a room electromagnetically shielded as a Faraday cage. Subjects were measured with an appropriately sized 128-channel EEG cap. Data were online filtered to a bandwidth of 0--134 Hz and digitized at 512 Hz. Participant responses and response time were measured and recorded in individual files as well as being marked on the EEG recording to allow for precise time-locking and categorization of EEG data epochs.

Cognitive and Motor Function Tests {#sec14a}
----------------------------------

Fifteen patients underwent psychological assessment using the ECAS within 4 weeks of the EEG recording. Additionally, ALSFRS-R was collected longitudinally by neurologists at the Irish national ALS specialty clinic in Beaumont Hospital. Total and ALS-specific ECAS scores within 30 days of EEG data collection were available for 15 patients, while ALS-nonspecific scores were available for 17 patients, and ALSFRS-R scores were available for 14 patients. Three additional patients had ALSFRS-R data within 3 months before and after the EEG recording date. Using the data from these two time points, ALSFRS-R scores for these three patients were estimated by interpolation assuming linear decline such that ALSFRS-R scores were available for 17 patients in total. Scores are summarized in [Table 1](#TB1){ref-type="table"}. Of those patients who performed abnormally in the ECAS, two had abnormal ALS-nonspecific scores but not total or ALS-specific scores, one had an abnormal ALS nonspecific score but could not complete the language, fluency, and spelling tasks to provide remaining scores, and one performed abnormally in total and ALS-specific scores but not in their ALS-nonspecific score.

Data Analysis {#sec15}
=============

Signal Preprocessing {#sec16}
--------------------

Signal preprocessing was performed using custom MATLAB (R2014a and R2016a, Mathworks Inc.) scripts and the EEGLAB ([@ref7]) and FieldTrip ([@ref31]) toolboxes. Data were filtered using a 0.3-Hz dual-pass fifth-order Butterworth high-pass filter and a 30-Hz dual-pass 117th-order equiripple finite impulse response low-pass filter. Highly contaminated and nonstereotyped artifacts were removed by visual inspection before epoching data from 200 before the stimulus to 900-ms poststimulus. In cases where responses occurred 150 ms or less after stimulus onset, trials were rejected and counted as an "anticipation error." Stereotyped artifacts (e.g., eye blinks, eye movements, and noisy single electrodes) were then removed by independent component analysis ([@ref7]). Data were common average referenced, and mean baseline amplitude was subtracted. Mean correct Go (clicking upon a nonthree digit) and NoGo (not clicking upon a "3" digit), ERPs were calculated for each participant. Due to low error number, there were an insufficient number of clean epochs for incorrect trial-associated ERP analysis. The mean number of included artifact-free correct Go/NoGo trials was 810.13/82.22 for patients and 815.42/82.79 for controls out of a maximum of 897/111.

Sensor Space Analysis {#sec17}
---------------------

Electrodes of primary interest were chosen based on established topographic maps of the SART N2 and P3 peaks ([@ref44]; [@ref37]). Four characteristics of the N2 and P3 peaks of each mean Go and NoGo epoch were measured in Fz, FCz, Cz, and Pz electrodes. Namely, the peak (maximal positive amplitude for P3, maximal negative amplitude for N2) amplitude and latency, mean amplitude, and area of the peak within the 220--350-ms and 350--550-ms time windows associated with N2 and P3, respectively. These time windows were chosen based on visual inspection of group mean ERPs and the existing SART--ERP literature ([@ref44]; [@ref20]; [@ref17], [@ref18]; [@ref21]). Time windows for quantifying peaks of interest were also limited to a maximum of 200 ms to facilitate baseline correction in source analysis (which required matching baseline and peak time windows) while using the same windows for sensor and source analysis.

For assessment of correlations with cognitive performance measures, where similarly significant correlations existed between performance measures and all peak size measures (peak amplitude, mean amplitude, and mean area), we report *P* and $\documentclass[12pt]{minimal}
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Source Space Analysis {#sec18}
---------------------

Channels with continuously noisy data were excluded (excluded channels mean \[range\] in controls: 0.18 \[0--4\] and patients: 0.22 \[0--4\]), and data from these channels were modeled by spline interpolation of neighboring channels. Source localization was performed using custom MATLAB scripts and LCMV beamforming ([@ref42]) as implemented in the FieldTrip toolbox. Boundary element head models ([@ref13]) incorporating geometries for the brain, skull, and scalp tissues were generated using the ICBM152 MRI template ([@ref12]), as template-based and individualized boundary element head models are found to provide comparable localization accuracy ([@ref13]; [@ref8]).

LCMV was used to estimate brain power maps for the Go and NoGo trails during two time windows, 220--350- and 350--550-ms poststimulus onset, to localize sources of the N2 and P3 ERPs, respectively. Localization was performed of Go and NoGo trials, as well as of the corresponding baseline windows of equal duration (N2: −130 to 0 ms, P3: −200 to 0 ms). Source localizations were performed using common spatial filters (estimated separately for Go and NoGo and for N2 and P3) calculated from epoched data spanning the start of the peak's baseline window to the end of that peak's time window. These common spatial filters were then used to source localize baseline and peak time windows separately. Covariance matrices, used by LCMV, were calculated for individual trials and mean averaged. Regularization of the covariance matrices was implemented at 5% of the average variance of EEG electrodes for each subject separately. Sources within the brain volume were modeled by a grid with 10-mm resolution. The leadfield matrix was normalized to avoid potential norm artifacts ([@ref19]). Go and NoGo source activities are reported with baseline correction as 10·log~10~(Power~peak~/Power~baseline~), with the difference between Go and NoGo source activity reported as 10·log~10~(Power~NoGo~/Power~Go~).

Statistics {#sec19}
==========

Behavioral Analysis {#sec20}
-------------------

Group-level comparisons of performance during the SART were implemented with Mann--Whitney *U* test. Adaptive false discovery rate (FDR) of 5% was implemented to correct for multiple comparisons, calculated by the Benjamini--Hochberg method ([@ref2]). *P* values are reported as uncorrected values were significant (determined by a corrected value of \< 0.05).

### Sensor Space Analysis {#sec21}

A four-factor ANOVA was performed for each of the four peak characteristics for both N2 and P3, resulting in eight ANOVA. For each ANOVA the variables included were sex (male or female, accounting for nongender imbalance), trial type (Go or NoGo), electrode (Fz, FCz, Cz, or Pz), and group (ALS patient or control). Post hoc analysis was implemented by Tukey's honestly significant difference ([@ref23]). Adaptive false discovery rate (FDR) of 5% was implemented to correct post hoc *P* values for multiple comparisons as described for behavioral analysis.

### Source Space Analysis {#sec22}

A 10-mm grid in the brain volume yields 1726 sources including white matter. To analyze these high-dimensional data, a 10% false discovery rate ([@ref1]) was used as a frequentist method for determining significant source activity differences. Discrimination ability between patients and controls is quantified by AUROC ([@ref16]). Empirical Bayesian inference ([@ref10]) was used to calculate the Bayesian posterior probability and statistical power.

*Neuropsychology correlation*

Spearman's rank correlation was used to test the association of the changes in EEG measures (peak characteristics or mean power within a cortical region) and cognitive and functional measures based on interindividual differences. These measures were as follows: Performance in the SART task during EEG collection, performance in the Delis--Kaplan color word interference task (CWIT) ([@ref6]), ECAS scores, and ALSFRS-R scores. Multiple comparison correction was implemented using FDR ([@ref2]) set to 5%. For source-level correlation analysis, mean power was calculated for brain regions identified as major sources of peak activity, defined by the Automated Anatomical Labelling atlas ([@ref39]). Where significant correlations are reported regarding Go and NoGo combination measures, for example, total (Go and NoGo) performance accuracy or the difference between NoGo and Go ERP measures, the relationship was verified not to be due to only Go or NoGo trials.

Results {#sec23}
=======

Performance {#sec24}
-----------

Patients (*n* = 23) and controls (*n* = 33) did not differ significantly in response time or accuracy. However, patients committed significantly more anticipation errors (patient mean \[standard deviation\]: 8.73% \[13.85%\], control mean \[standard deviation\]: 1.01% \[3.26%\], *P* = 0.0031).

Control Characteristics {#sec25}
-----------------------

### Sensor Space {#sec26}

Mean patient and control Go and NoGo ERPs in electrodes of interest are shown in [Figure 1](#f1){ref-type="fig"}. ANOVAs did not reveal any significant gender effects on waveform features.

![Mean Go (blue) and NoGo (red) trial ERPs in controls and ALS patients. N2 peaks are visible in the NoGo trial ERP in Fz and Cz in the 220--350-ms window. P3 peaks are present in the 350--550-ms window in both Go and NoGo trial ERPs in all electrodes. Green asterisks represent significantly larger P3 peak amplitudes in NoGo versus Go trials. Red asterisks represent significantly larger (more negative) N2 peak amplitudes in NoGo versus Go trials. Black asterisks represent significant differences in NoGo-Go N2 peak amplitude between ALS patients and controls. ^\*\*^*P* \< 0.01, ^\*\*\*\*^*P* \< 0.0001. CON: controls.](bhaa076f1){#f1}

*N2:* N2 in Cz was significantly smaller in Go trials than NoGo trials in controls (peak area *P* = 0.018, peak amplitude *P* = 0.006). This N2 difference significantly correlated with faster response times (*P* = 8.08 × 10^−6^, rho = 0.69) and poorer NoGo accuracy (*P* = 0.0086, *rho* = 0.45) in controls ([Fig. 2*A*](#f2){ref-type="fig"}).

![Correlations between NoGo minus Go (NoGo-Go) N2 peak amplitude in Cz and cognitive task performance. (*A*) Correlation with response time and NoGo trial accuracy in controls demonstrates that those with smaller NoGo versus Go N2 peak differences had significantly faster response times and better NoGo accuracy. (B) Correlation with patient ECAS total and ALS-specific score demonstrates that those with smaller (less negative) N2 peak differences had lower ECAS scores.](bhaa076f2){#f2}

*P3*: P3 was significantly smaller for Go trials compared with NoGo trials in all four electrodes of interest ([Fig. 1](#f1){ref-type="fig"}, Tukey's post hoc *P* = 3.50 × 10^−5^--8.15 × 10^−7^). P3 peak latency in the Pz electrodes was also significantly greater in NoGo trials compared with Go trials (*P* = 5.12 × 10^−7^). Controls with later responses had later NoGo P3 peaks in Fz (*P* = 0.0020, rho = 0.52), while those with better NoGo accuracy had smaller Go P3 peaks in Cz (*P* = 0.011, rho = −0.43) and FCz (*P* = 0.0034, rho = −0.50), and those with better Go accuracy had larger NoGo P3 peaks in Pz (*P* = 0.0070, rho = 0.46). Better overall accuracy also correlated significantly with smaller NoGo P3 peaks in Fz (*P* = 1.26 × 10^−4^, rho = −0.62). Correlations are illustrated in [Fig. 3*A*](#f3){ref-type="fig"}--*D*.

![Correlations between P3 peak characteristics and SART performance. In controls, (*A*) later responses correlate with later P3 peaks in Fz during NoGo trials, (*B*) better NoGo accuracy inversely correlates with Go P3 peak size in Cz, (*C*) Go accuracy positively correlates with NoGo P3 peak amplitude in Pz, and (*D*) overall accuracy inversely correlates with NoGo P3 peak amplitude in Fz. In all participants, (*E*) later responses correlate with longer peak latency and (*F*) smaller peak amplitude during Go trials in Cz. In patients, (*G*) greater overall accuracy correlates with longer Go P3 peak latency in Cz.](bhaa076f3){#f3}

### Source Space {#sec27}

*N2:* The left primary motor cortex and bilateral **dorsolateral prefrontal cortex (**DLPFC) and lateral posterior parietal cortex (PPC) were identified as primary mean sources of both Go and NoGo N2, with greater bilateral precuneus activation during NoGo trials ([Fig. 4](#f4){ref-type="fig"}).

![Primary sources (regions with top 5% power) of N2 during Go trials, NoGo trials, and NoGo trials relative to Go trials ("difference") in controls (first rows) and patients (second rows).](bhaa076f4){#f4}

*P3:* Mean P3 sources were similar to those of N2 for Go and NoGo trials, although controls showed decreased left insular, PPC, and DLPFC activity during NoGo trials relative to Go trials ([Fig. 5](#f5){ref-type="fig"}).

![Primary sources (regions with 5% power) of P3 during Go trials, NoGo trials, and NoGo trials relative to Go trials ("difference") in controls (first rows) and patients (second rows).](bhaa076f5){#f5}

ALS Patient Differences {#sec28}
=======================

Differences in peak and source measures between patients and controls are summarized in [Table 2](#TB2){ref-type="table"}.

###### 

Significant differences in ALS sensor-level and source-level measures compared with controls

  Sensor level (ERP peaks)                                                                          
  -------------------------- --------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------
  N2                         NoGo      Cz                                                           ↓ Peak amplitude
                             FCz       ↓ Peak amplitude                                             
  NoGo-Go                    Cz        No correlation to task performance                           
  P3                         Go        Cz                                                           Later peak positively correlates with greater overall accuracy, no correlation between peak amplitude and accuracy.
  NoGo                       Fz, Pz    No correlation between amplitude or latency to performance   
  Source level                                                                                      
  Peak                       Trial     Source                                                       Change in ALS
  P3                         NoGo-Go   Left posterior parietal and insular cortex                   ↑ Activation, area under receivership operating curve \> 0.75

Sensor Space (ERP) Differences {#sec29}
------------------------------

*N2:* Patients did not show a significant difference in the N2 peak between Go and NoGo trials. Correspondingly, N2 was significantly smaller for NoGo trials in ALS patients compared with controls in FCz (*P* = 5.08 × 10^−4^) and Cz (*P* = 0.001). Unlike controls, the difference in N2 between Go and NoGo trials did not correlate with SART performance; however those patients with greater N2 NoGo-Go differences in Cz had higher ECAS total (*P* = 0.0022, rho = −0.73, [Fig. 2*A*](#f2){ref-type="fig"}) and ALS-specific (*P* = 0.017, rho = −0.61) scores, indicating better cognitive performance, particularly in tasks of executive function and language ([Fig. 2*B*](#f2){ref-type="fig"}).

*P3:* The P3 peak did not differ significantly between patients and controls for any trial type or characteristic. Patients and control with longer response times had later (*P* = 0.0074, rho = 0.35), smaller (*P* = 2.31 × 10^−5^, rho = −0.53) Go P3 peaks in Cz ([Fig. 3*E*,*F*](#f3){ref-type="fig"}). Otherwise, patients did not display the correlations between their P3 peak characteristics and task performance that were observed for controls. Overall accuracy was found to significantly correlate with later Go P3 peaks in Cz in patients (*P* = 0.0069, rho = 0.54, [Fig. 3*G*](#f3){ref-type="fig"}).

Source Space Differences {#sec30}
------------------------

*N2:* Patients showed similar patterns of source activity to controls during N2 ([Fig. 4](#f4){ref-type="fig"}).

*P3:* While similar locations of source activity were observed in patients and controls during Go and NoGo trials, ALS patients showed similar differences between NoGo and Go source differences to N2 during P3 ([Fig. 5](#f5){ref-type="fig"}), unlike controls. Correspondingly, ALS patients displayed widespread, significantly increased activity during NoGo trials relative to Go trials when compared with controls, with the most discriminant differences (AUROC \>0.75) being in the left inferior parietal lobule and left insula ([Fig. 6](#f6){ref-type="fig"}).

![P3 sources with statistically significant differences in activity in ALS compared with controls. Differences between NoGo and Go trial source activity during the P3 peak were compared between ALS patients and controls. All highlighted areas represent significant (FDR = 10%, type II error=0.38 Bayesian Posterior probability=0.87) increases in power with heat map values representing AUROC = --0.5 (i.e., perfect discrimination = 0.5). Orthogonal MRI scans show only those differences with an AUROC \>0.75, that is, very good discriminators. AUROC: area under the receivership operating curve.](bhaa076f6){#f6}

Source Space Correlations in ALS Patients {#sec31}
-----------------------------------------

Greater right precuneus power during P3 in NoGo relative to Go trials negatively correlates with CWIT inhibition score (*P* = 0.0015, rho = −0.91, [Fig. 7](#f7){ref-type="fig"}). As greater scores in this task indicated poorer behavioral inhibition, this relationship demonstrated that the abnormal activation of this area was associated with greater preservation of this executive function.

![Greater behavioral inhibition in ALS is associated with increased right precuneus activity during NoGo P3 relative to Go P3. Higher CWIT inhibition score indicates poorer behavioral inhibition.](bhaa076f7){#f7}

Discussion {#sec32}
==========

This study demonstrates for the first time the specific cortical structures that contribute to performance of the SART and quantifies the relationship between SART performance measures and underlying cognitive performance. Furthermore, we have identified abnormalities in cortical function which strongly correlate with executive impairment in ALS.

ERP Peak Characteristics {#sec33}
------------------------

At sensor level, our control findings were consistent with the literature, demonstrating the robustness of SART-associated ERPs. N2 and P3 peaks were present in the anticipated time windows and, as expected, larger for healthy individuals during correct response omission.

*Central N2*

NoGo N2 was maximal in Cz, as previously established. We identified that smaller differences in N2 size between NoGo and Go trials were associated with faster reaction times. We also identified a correlation between smaller NoGo N2 peaks and better NoGo trial accuracy. As the N2 peak has been associated with automated motor response control ([@ref44]), this may reflect greater ability to withhold and greater response speed where less cortical resources are required to inhibit upper motor neurons.

Notably, these correlations were not present for ALS patients, which may represent the compensatory engagement of alternative cortical resources. Alternatively, the established malfunction of inhibitory cells of the motor system ([@ref29]) in addition to upper motor neurons may lead to reduction in NoGo N2 in combination with slowing reaction times.

### Frontal and Parietal P3 {#sec34}

The P3 peak was present across the frontoparietal axis of sensors during NoGo trials in keeping with the SART--ERP literature ([@ref44]; [@ref17]; [@ref37]). Such spatially distributed P3 peaks associated with other cognitive tasks have been shown to consist of two distinct entities, namely, the frontal and parietal P3. Frontal P3 peaks have been associated with orientation to novel stimuli, declining over task duration although remaining elevated in distractible children ([@ref22]) and those with panic disorder ([@ref35]). By contrast, parietal P3 peaks are associated with working memory and attention to target stimuli ([@ref35]; [@ref22]).

Here we have identified similarly distinct behaviors in the frontal and parietal SART-associated P3 peaks. In frontocentral electrodes, P3 latency related to response timing and is likely to provide an index of orientation speed. Smaller frontocentral P3 peaks were associated with more accurate performance in the opposite trial type (i.e., better Go performance with smaller NoGo peaks and vice versa). By contrast, larger NoGo parietal P3 was associated with better Go trial performance. This is in keeping with the cognitive resources required for accurate Go and NoGo SART performance. The engagement of working memory and attentional control was indicated by a large NoGo parietal P3, and quick orientation to the task was indicated by earlier, smaller frontal P3 peaks ([@ref35]; [@ref22]).

The orienting frontal P3 is typically earlier than the parietal P3; however, it has been hypothesized that frontal P3 peaks may also encompass compensatory prefrontal engagement due to parietal decline ([@ref41]). This may explain why ALS patients, but not in controls, demonstrated greater Cz P3 peak latencies during Go trials in those with better accuracy.

Cortical Source Imaging {#sec35}
-----------------------

At source level both Go and NoGo N2 and P3 peaks were associated with extensive prefrontal and motor cortex engagement, particularly in the left cortex, in keeping with the use of the right hand for task performance. Such widespread cortical engagement is expected, given the numerous cognitive and motor domains required for accurate task performance. The medial PPC (i.e., the precuneus) was additionally engaged during NoGo trials relative to Go trials during N2, in keeping with its role in both voluntary attention shifting and movement control ([@ref4]). By contrast, the left insula and inferior parietal lobule show lower power in NoGo trials relative to Go trials during P3, in keeping with the role of the left insula in the salience network ([@ref40]) and goal-directed behavior ([@ref43]). The left inferior parietal lobule has been attributed numerous functions, among which are object-directed action ([@ref5]) and expectancy violation ([@ref30]). This engagement of numerous cortical structures by different elements of the SART highlights the range of cortical pathologies that could contribute to decline in SART performance measures. While SART--ERP analysis can temporally dissect the cause of such performance decline, it is clear from source imaging that a specific peak abnormality could also result from dysfunction in several different cortical structures. Source imaging can therefore not only inform on source contributing to cognitive and motor symptoms but could also discriminate between psychiatric or neurodegenerative syndromes with similar symptoms driven by differing cortical pathologies.

Quantifying Cortical Pathology Driving Cognitive Impairment in ALS {#sec36}
------------------------------------------------------------------

ALS patients maintained similar Go and NoGo accuracy but were more likely to attempt to complete trials rapidly clicking before cognitively processing the presented digit, resulting in greater anticipation error. Despite sensor-level differences, patients and control activity did not differ significantly at a specific N2 source. This is likely to be a function of spatially distributed differences in activity which summate in signals captured by individual electrodes at source level. Patients did, however, demonstrate very similar elevation in precuneus activity during NoGo relative to Go trials in both N2 and P3. As this elevation in right precuneus activity during P3 was associated with greater behavioral inhibitory function, this may represent a compensatory recruitment of this region. Indeed, this exemplifies the utility of source localized EEG during task performance for quantifying cognitive pathology during presymptomatic phases of compensatory cortical activity that are more amenable to clinical intervention.

ALS patients demonstrated additional widespread cortical activity elevation during NoGo relative to Go trials during P3, particularly in the left insula and inferior parietal lobule, which showed very good discrimination between patients and controls (AUROC \> 0.75). Such posterior parietal hyperengagement has previously observed during involuntary attention switching ([@ref27], [@ref9]) and at rest ([@ref34]; [@ref9]) and may provide additional discriminatory power in the development of cortical diagnostic biomarkers. A previous study in Huntington's disease identified reduced activity in the left DLPFC ([@ref3]), right medial frontal, and anterior cingulate cortex during the NoGo P3, while we find hyperactivity in these areas in ALS, highlighting the ability of this task to identify differing underlying cortical pathologies in neurodegenerations with overlapping cognitive and behavioral symptoms.

We acknowledge that while these cross-sectional data serve well to characterization of ALS disease heterogeneity, these measures demand larger-scale studies for adequately powered subgroup analysis. Additional larger, longitudinal studies will be required to further evaluate the application of this technology in clinical trials and disease prognostics.

In conclusion, here we have provided a spatially and temporally precise description of the cortical activity which underlies the N2 and P3 peaks of the randomized SART--ERP in healthy adults and illustrated the applications of this methodology for interrogating cognitive and motor malfunction in a complex neurodegenerative disease. While larger patient recruitment is required for further investigation of the use of SART as an ALS biomarker, we have established that the SART--ERP and its underlying source activity can provide objective, quantitative, early markers of cognitive and motor pathology. The localization of EEG recorded during a wider battery of cognitive, motor, and sensory tasks has considerable potential to provide patient-specific profiles of cortical network disturbance which could in turn provide biomarkers that improve patient subgrouping, clinical trial stratification, and prognostic accuracy.
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